Igg Igm Spike

Mouse phosphatidylinositol antibody IgG/IgM,PI Ab-IgG/IgM

YLA0711MO-48T 48T
EUR 465

Human IgG antibody Laboratories manufactures the igg igm spike reagents distributed by Genprice. The Igg Igm Spike reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike IgM. Other Igg products are available in stock. Specificity: Igg Category: Igm Group: Spike

Human Cytomegalovirus IgG / IgM, Toxoplasma IgG / IgM, Rubella IgG Rapid Test Kit

20 tests
EUR 410.4

Human IgA, IgG and IgM AssayLite Multiplex Fluorescent Immunoassay Kit

96 Well Plate
EUR 1472.4

Rat phosphatidylinositol antibody IgG/IgM,PI Ab-IgG/IgM ELISA Kit

96T
EUR 590.4

Rat phosphatidylinositol antibody IgG/IgM,PI Ab-IgG/IgM ELISA Kit

48T
EUR 409.2

Mouse phosphatidylinositol antibody IgG/IgM,PI Ab-IgG/IgM ELISA Kit

96T
EUR 586.8

Mouse phosphatidylinositol antibody IgG/IgM,PI Ab-IgG/IgM ELISA Kit

48T
EUR 405.6

Mouse Phosphatidylinositol antibody IgG/IgM (PI Ab IgG/IgM) CLIA Kit

96 tests
EUR 990

Spike information

Spike Glycoprotein Antibody

20-abx300551
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

90-SOW MATRIX SPIKE

CLPP-MS90H 1ML
EUR 258

91-SOW Matrix Spike

CLPP-MS91H 1ML
EUR 103.2

Mouse Monoclonal Anti-Porcine epidemic diarrhea virus Spike protein S1 (PEDV-S1) IgM, unlabeled

PEDV13-M 100 ul
EUR 578.4

SARS (IN3) Spike Peptide

3225P 0.05 mg
EUR 197.7
Description: (IN) SARS (IN3) Spike peptide

SARS (IN1) Spike Peptide

3221P 0.05 mg
EUR 197.7
Description: (IN) SARS (IN1) Spike peptide

SARS (IN2) Spike Peptide

3223P 0.05 mg
EUR 197.7
Description: (IN) SARS (IN2) Spike peptide

91 SOW Surrogate Spike

CLPP-S91 2ML
EUR 247.2

EPH Surrogate Spike Mix

NJDEP-EPH-SS 1ML
EUR 242.4

SARS-CoV Spike Protein

abx060655-1mg 1 mg
EUR 2030.4

SARS-CoV Spike Antibody

3225-002mg 0.02 mg
EUR 206.18
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3225-01mg 0.1 mg
EUR 523.7
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3219-002mg 0.02 mg
EUR 206.18
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3219-01mg 0.1 mg
EUR 523.7
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3221-002mg 0.02 mg
EUR 206.18
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3221-01mg 0.1 mg
EUR 523.7
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3223-002mg 0.02 mg
EUR 206.18
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.